文献速递骨软组织肉瘤与黑色素瘤

硬化性上皮样纤维肉瘤与低级别纤维黏液样肉瘤:全国NETSARC+系列330例患者13年表现与结局比较

Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years.
PubMed 文献 · Eur J Cancer · 2023-11-23

基于NETSARC+全国数据库,比较2010年以来330例硬化性上皮样纤维肉瘤(SEF)与低级别纤维黏液样肉瘤(LGFMS)患者特征与结局。SEF诊断时转移比例更高、原发灶更大、R0切除率更低、无事件生存更差,但复发后中位总生存两组相似。

要点

  • SEF诊断时转移占30%,LGFMS仅4%(p<0.0001)。
  • LGFMS手术标本R0率41%,SEF仅16%(p<0.001)。
  • SEF中位无事件生存32个月,LGFMS为136个月(p<0.0001)。

核心结论

  • SEF与LGFMS虽共享相近的分子改变,但自然史、临床表现和结局不同,SEF转移复发风险更高。
  • 复发后生存时间长于其他肉瘤,且SEF与LGFMS相似。

研究设计与样本

  • NETSARC+为覆盖26个肉瘤参考中心、设有专门多学科肿瘤委员会(MDTB)的网络,自2010年起肉瘤病理复核为强制要求,患者特征收录于全国数据库。
  • 纳入2010年以来NETSARC+数据库中330例SEF或LGFMS患者,比较两组特征与结局。
  • SEF组73例,LGFMS组257例。

主要发现

  • SEF组女性35/73(48%),LGFMS组女性125/257(49%)。
  • SEF组内脏、骨和躯干原发部位更多(p<0.001)。
  • SEF组诊断时转移30%,LGFMS组4%(p<0.0001)。
  • LGFMS原发肿瘤中位大小51 mm(范围10-90),SEF为80 mm(范围20-320)(p<0.001)。
  • LGFMS患者中位年龄较SEF患者年轻12岁(43岁[范围4-98] vs 55岁[范围10-91],p<0.001)。

关键数值与推荐

  • SEF组接受新辅助治疗16%,LGFMS组9%(p=0.05)。
  • LGFMS组51%在参考中心首先手术,SEF组26%(p<0.001)。
  • 手术标本R0率LGFMS组41%,SEF组16%(p<0.001)。
  • SEF与LGFMS中位无事件生存(EFS)分别为32个月与136个月(p<0.0001)。
  • LGFMS与SEF的50个月总生存(OS)分别为93%与81%(p=0.05);中位OS未达到。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Sclerosing Epithelioid Fibrosarcoma (SEF) and Low Grade Fibromyxoid Sarcoma (LGFMS) are ultrarare sarcomas sharing common translocations whose natural history are not well known. We report on the nationwide exhaustive series of 330 patients with SEF or LGFMS in NETSARC+ since 2010. PATIENTS AND METHODS: NETSARC (netsarc.org) is a network of 26 reference sarcoma centers with specialized multidisciplinary tumor boards (MDTB). Since 2010, (i) pathological review has been mandatory for sarcoma,and (ii) tumour/patients' characteristics have been collected in the NETSARC+ nationwide database. The characteristics of patients with SEF and LGFMS and their outcome are compared. RESULTS: 35/73 (48%) and 125/257(49%) of patients with SEF and LGFMS were female. More visceral, bone and trunk primary sites were observed in SEF (p < 0.001). 30% of SEF vs 4% of LGFMS patients had metastasis at diagnosis (p < 0.0001). Median size of the primary tumor was 51 mm (range 10-90) for LGFMS vs 80 (20-320) for SEF (p < 0.001). Median age for LGFMS patients was 12 years younger than that of SEF patients (43 [range 4-98] vs 55 [range 10-91], p < 0.001). Neoadjuvant treatment was more often given to SEF (16% vs 9%, p = 0.05). More patients with LGFMS were operated first in reference centers (51% vs 26%, p < 0.001). The R0 rate on the operative specimen was 41% in LGFMS vs 16% in SEF (p < 0.001). Median event-free survival (EFS) of patients with SEF and LGFMS were 32 vs 136 months (p < 0.0001). The median overall survival (OS) was not reached. Fifty-months OS was 93% vs 81% for LGFMS vs SEF (p = 0.05). Median OS was 77 months after first relapse, similar for SEF and LGFMS. In multivariate analysis, age, tumor size, metastasis at diagnosis were independent prognostic factors for OS in LGFMS. CONCLUSIONS: Although sharing close molecular alterations, SEF and LGFMS have a different natural history, clinical presentation and outcome, with a higher risk of metastatic relapse in SEF. Survival after relapse is longer than with other sarcomas, and similar for SEF and LGFMS.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Blay JY, Tlemsani C, Toulmonde M, et al. Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years. Eur J Cancer. 2023. PMID: 38008029. doi:10.1016/j.ejca.2023.113454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。